Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 281 - 290 of 333

<< Previous | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | Next >>

Last updated: 20th February 2008

Patent No.: US 5856127
Antimicrobial peptides.
Applicant: Powell WA, Maynard CA (1999)
The present invention is directed to antimicrobial polypeptides and to nucleic acid molecules encoding these antimicrobial polypeptides. The polypeptide consists of from 15 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix. Expression vectors, host cells, and transgenic plants, as well as methods of producing plants having improved resistance to fungal and bacterial infestation, are also provided.

Patent No.: US 5855882
Methods for inhibiting the cross-linking of advanced glycosylation endproducts.
Applicant: Li YM, Vlassara H, Cerami A (1999)
The present invention is directed to methods for inhibiting the cross-linking of advanced glycosylation endproducts in a subject suspected of having elevated levels of AGEs by using the unexpected discovery that certain antibacterial proteins, in particular lysozyme and particular fragments thereof, bind to advanced glycosylation endproducts (AGEs) with high affinity, and that this binding activity is substantially noncompetitive with binding of bacterial carbohydrates to the antibacterial proteins. Accordingly, the invention relates to therapeutic methods for treating diseases and disorders associated with increased levels of AGEs, by using compositions having associated therewith a molecule having a hydrophilic loop domain, which domain is associated with AGE-binding activity, and compositions comprising such a domain to remove AGEs from biological material. The invention further relates to compositions for inhibiting the cross-linking of AGEs in a subject in need of such therapy.

Patent No.: US 5851822
Inflammation-induced expression of a recombinant gene.
Applicant: Munford RS (1999)
The present invention describes methods of controlling and regulating the inflammatory reaction generated in response to various toxins, immunogens, pathogens and autoimmune insults. The method employs a vector that includes an anti-cytokine protein or antibacterial protein gene under the control of a cytokine responsive promoter. In animal models, adenoviral vectors successfully delivered the vectors to hepatic cells and were subsequently shown to respond only to stimulation by induced cytokines.

Patent No.: US 5849490
Inducible defensin peptide from mammalian epithelia.
Applicant: Schonwetter BS, Zasloff MA (1999)
The present invention relates to an inducible antimicrobial peptide designated lingual antimicrobial peptide (LAP) which has antibacterial and antifungal activity and which can be obtained from mammalian epithelium. The prepro- and the pro- precursors of LAP are also provided. The present invention also relates to cDNA encoding LAP, the prepro- precursor or the pro-lingual precursor. In addition, methods of treating microbial infection of the epithelia are provided. Such infections can be treated by contacting the epithelia with an antimicrobially effective amount of a purified mammalian epithelial LAP or by administering a component which cause endogenous production or up-regulation of LAP.

Patent No.: WO 9858061
Mammalian cysteine-rich soluble protein and their cDNAs.
Applicant: Franz-Bacon K, Gorman DM, McClanahan TK (1998)
Nucleic acids encoding a new family of mammalian small cysteine rich soluble proteins (CRSPs), reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. CDNAs for mouse, rat and human CRSPs were cloned and sequenced. Mouse CRSP2 was mapped to chromosome 16 in a region which is syntenic with the part of human chromosome 3 at which human CRSP10 was mapped. The expression pattern of these proteins suggests a role in immunol. function, esp. inflammatory conditions. The carboxy termini of the CRSPs exhibit significant sequence similarity to the defensins. The amounts of protein expressed and the exon structure of the CRSPs seem to match with that of the defensins. These similarities suggest that CRSPs have a direct antimicrobial function.

Patent No.: WO 9851794
A human beta-defensin 2 and a cDNA encoding it.
Applicant: Olsen HS, Ruben SM (1998)
A novel human antimicrobial peptide member of the defensin superfamily is described and a cDNA encoding it is cloned. Levels of the protein and of expression of the gene in lung, lymph node, and cornea can be used as indicators of function of the immune system and in the diagnosis of immune disorders. The protein can be used in the treatment of a no. of infections and in the prevention of disease, esp. in patients with AIDS. Strategies for manuf. of the protein by expression of the cloned cDNA are described.

Patent No.: WO 9840401
Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics.
Applicant: Fraser JR, West MHP, Mcnicol PJ (1998)
Compns. and methods for treating infections, esp. bacterial infections, are provided. Cationic peptides in combination with an antibiotic agent are administered to a patient to enhance the activity of the antibiotic agent, overcome tolerance, and overcome acquired or inherent resistance. Thus, a combination of antimicrobial agent and cationic peptide that breaks tolerance results in a decrease of min. bacterial concn. (MBC) to min. inhibitory concn. (MIC) ratio to <32. The combination of vancomycin and MBI 26 overcomes the tolerance of Enterococcus casseliflavus and E. faecalis with MBC/MIC ratio of 1-8 compared to that of 32 to >256 for vancomycin alone.

Patent No.: WO 9840091
Defensin- and bactenecin-based microbicidal peptides and methods of use.
Applicant: Periathamby AR (1998)
Microbicidal peptides are provided which represent bioactive domains, demonstrating antimicrobial activity against at least one microbial pathogen, of the amino acid sequences of naturally occurring defensins or bactenecins. The microbicidal peptide may also be an analog having at least 50% identity with the bioactive domain, but further incorporates substitutions with one or more natural, or uncommon, amino acids or chem. moieties for improving structural and/or functional properties of the peptide. Also provided are methods of using the microbicidal peptides in formulations for antimicrobial therapy, or for incorporation onto or into surfaces which come into contact with microorganisms.

Patent No.: WO 9839011
Photosensitizer conjugates for pathogen targeting.
Applicant: Hasan T, Hamblin MR, Soukos N (1998)
Conjugate mols. which include photosensitizer compns. conjugated to non-antibody non-affinity pair targeting moieties and methods of making and using such conjugates are described. The non-pair member moiety includes a bacterial, fungal, or animal (e.g. mammalian or human) small antimicrobial peptide: histatin, defensin, cecropin, magainin, gram-pos. bacteriocin, and antibiotic peptide, and the photosensitizer is a porphyrin or deriv. Thus, polylysin-chlorin e6 conjugates, histatin-chlorin e6 conjugates, and histatin-polylysine-chlorin e6 conjugates of varying charges were synthesized and tested for uptake by Porphyromonas gingivalis and phototoxicity of these conjugates for killing bacteria while sparing mammalian cells.

Patent No.: WO 9806863
Plasmid vector for polynucleotide vaccines.
Applicant: Nelson EL, Nelson PJ (1998)
The invention is a "humanized" polynucleotide vector vaccine which uses covalent closed circular plasmid DNA, "naked DNA", to express target antigens. The vector is non-replicating in mammalian cells but is capable of extended stable expression of the target sequences in skeletal muscle and professional antigen presenting cells generating an immune response to the target antigen in immunized individuals. The polynucleotide vector is particularly useful in accommodating monomorphic and polymorphic nucleic acid sequences encoding tumor antigens via PCR technol. Thus, plasmid pITL was designed to contain minimal exogenous DNA and to be maximally humanized, with elements of the plasmid except the origin of replication and selection element (supF) being derived from human genetic elements. The minimal ColE1 origin of replication comprises base pairs 712-1164 of pITL, the SupF sequence comprises base pairs 495-701, the minimal RANTES promoter comprises base pairs 1177-1425, the stuffer noncoding sequence comprises base pairs 1-221 and the combined splice and poly(A) sequences comprises base pairs 22-481. Base pairs 482-494, 602-611, and 1165-1176 are extraneous, noncoding sequences derived from plasmids from which the component sequences were excised. The polynucleotide vaccine vector has the following characteristics: (1) is selectable for growth and prodn. of a polynucleotide vaccine product, (2) is capable of eukaryotic expression of one or more target antigens or antigenic epitopes, (3) is functional in selected tissue and selected cells of the inflammatory immune systems, (4) has minimal extraneous non-human DNA sequences to minimize potential toxicity, and (5) is capable of accepting target nucleic acid sequences from a no. of different transcripts. The vector is exemplified in Phase I and Phase I/II trials for anti-tumor vaccination with partial Her2/neu (c-erbB2) expression in advanced breast cancer.